| abstract |
Novel tumour selective anti-neoplastic agents are characterized, in that to customary antineoplastic agents are attached one or two very specific unbranched Ω-hydroxyalkyl, (Ω-hydroxy)alkenyl, Ω-(2,3-dihydroxypropyloxy)alkyl or an (Ω-(2,3-dihydroxypropyloxy))alkenyl groups R 2 and R 3 with 5 to 30 carbon atoms, forming a tumour selective conjugate as exemplified with the compounds of formulae I, II and III [] wherein R 1 is a customary pharmaceutically acceptable inorganic or organic leaving group and A is 1,2-dimethylene, 1,3-trim ethylene, 1,2-cyclopentylene or 1,2-cyclohexylene. These compounds as well as their pharmaceutically acceptable salts, ester and prodrug derivatives are valuable chemotherapeutics |